40 results about "Hemofiltration" patented technology

Disclosed herein is a clot treatment system having a filtering syringe, and associated devices and methods. The filtering syringe can be coupled to a catheter subsystem insertable into a patient. The filtering syringe can aspirate material (e.g., clot material, blood, etc.) from the patient through the catheter subsystem. The filtering syringe can include a plunger assembly, which can include one or more filters. Each of the filters can be configured to (i) allow at least a first portion of the aspirated material (e.g., blood) to pass through at least one of the filters, and (ii) prevent at least a second portion of the aspirated material (e.g., clot material) from passing through at least one of the filters.

The invention discloses a kidney organoid culture and multifunctional detection integrated micro-fluidic chip, which is characterized in that a first chip (top layer) is provided with six independent cell culture chambers, the bottom is provided with a porous membrane, glomerular cells differentiated by human induced pluripotent stem cells are inoculated, and a blood filtration function is simulated; the second chip (middle layer) is provided with a raw urine-like collecting chamber, and a porous membrane is used for receiving the filtrate and detecting final urine-like components; and the third chip (bottom layer) is inoculated with vascular endothelial cells to simulate renal tubule reabsorption and blood purification processes. According to the invention, glomerular filtration and renal tubule reabsorption full-function chains are coupled, and the limitation of single function simulation is broken through; the parallel culture room supports synchronous drug toxicity testing or disease modeling; a multi-valve dynamic control system can accurately simulate pathological microenvironments such as high glucose and renal toxicity; and in-situ multi-parameter real-time analysis is realized through three paths of detection outlets. The chip provides a highly bionic in-vitro platform for drug screening, diabetic nephropathy mechanism research and kidney injury model construction.

An artificial kidney configured to automatically or semi-automatically perform priming, procedure running, purging, flushing, and procedure ending. The artificial kidney is wearable and can be used while ambulating, sitting, and lying down. The artificial kidney can be used at home as a supplement to standard intermittent hemodialysis therapy in the clinic. In an example, the artificial kidney can be configured to perform alert event detection, start a timer, and take steps to resolving the alert event. The steps can include automated steps and can include instructions to be manually performed by the user (or the patient). If the alert event is resolved within a set time, the artificial kidney can continue to perform procedure running. If the alert event is not resolved within the set time, the artificial kidney performs the procedure ending.

A renal replacement apparatus (100), having a hemofilter (108); an extracorporeal blood circuit (102) configured to communicate blood from a patient (104), through the hemofilter, and back to the patient; and a flow measuring device (150) configured to measure at least one blood flow property as the blood is leaving the hemofilter and before the blood returns to the patient at a flow measuring device location (152), wherein the flow measuring device comprises at least one of a viscometer and a rheometer. Alternately, or in addition, the renal replacement apparatus may include thermomodulator system (222) including at least one thermomodulator configured to selectively heat and cool the blood in the extracorporeal blood circuit. The renal replacement apparatus (100) may have a controller (160). The controller may use artificial intelligence. Other embodiments are described herein.

This disclosure relates to medical fluid pumping systems and related devices and methods. In some aspects, a blood treatment system includes a user interface; a processor in communication with the user interface and configured to perform operations including: presenting instructions on the user interface, the instructions pertaining to at least one modality of a set of modalities, wherein the set of modalities include hemodialysis (HD), hemofiltration (HF), and hemodiafiltration (HDF), wherein the instructions pertain to a component of a blood treatment machine of the blood treatment system; receiving information associated with the component of the blood treatment machine; and eliminating modalities from the set of modalities to determine a modality of the blood treatment machine based on the received information.

An artificial kidney configured to automatically or semi-automatically perform priming, procedure running, purging, flushing, and procedure ending. The artificial kidney is wearable and can be used while ambulating, sitting, and lying down. The artificial kidney can be used at home as a supplement to standard intermittent hemodialysis therapy in the clinic. In an example, the artificial kidney can be configured to perform alert event detection, start a timer, and take steps to resolving the alert event. The steps can include automated steps and can include instructions to be manually performed by the user (or the patient). If the alert event is resolved within a set time, the artificial kidney can continue to perform procedure running. If the alert event is not resolved within the set time, the artificial kidney performs the procedure ending.

This invention provides a bedside hemofiltration method and system for elderly critically ill patients, comprising: analyzing the correlation between transmembrane pressure changes and venous pressure fluctuations under the control of vascular access type and puncture angle, based on a dynamic trend description, and simultaneously evaluating the corrective effect of signal compensation mechanisms on data accuracy to obtain a set of parameter correlation strengths; if some values ​​in the parameter correlation strength set exceed a preset threshold, then combining monitoring data on access infection risk and fluctuations in signal transmission distance, determining whether there is a chain reaction caused by access abnormality, and obtaining an abnormal chain reaction identifier; for the abnormal chain reaction identifier, determining the degree of danger of the abnormality to the overall system by analyzing the matching degree between access establishment time and attenuation frequency range, and obtaining a danger level classification result.

The utility model provides a blood or plasma protein concentration stabilizing device for a screening coefficient test, and belongs to the technical field of medical instrument detection. The blood or plasma protein concentration stabilizing device for the screening coefficient test comprises a pipeline I, a fibrinolysis mechanism is arranged at the bottom of the pipeline I, the fibrinolysis mechanism is installed in a temperature control fixing mechanism, a blood storage mechanism is further arranged in the temperature control fixing mechanism, and the fibrinolysis mechanism and the blood storage mechanism are communicated through a pipeline IV and a pipeline III. Two ends of the pipeline IV are fixedly connected with the side wall of the pipeline III. In-vitro real-time fibrinolysis can be realized through the fibrinolysis mechanism, the temperature control fixing mechanism, the blood storage mechanism, related pipelines and valves, and fibrous protein solids are prevented from blocking the pipelines, a filter or a concentrator; and the protein concentration in a blood circulation loop necessary for screening coefficient tests of a hemodialyzer, a hemodialysis filter, a blood filter and a blood concentrator is maintained and stabilized at 60g / L + / -5g / L.

The invention provides a sterilization process of a glucose-containing double-chamber bag blood filtration replacement liquid, a to-be-sterilized product is a filled and sealed blood filtration replacement liquid, the sterilization adopts a moist heat sterilization process, the sterilization temperature is 121 DEG C, the heating time is 1500-3800 s, the sterilization time is 25-30 min, and the cooling time is greater than or equal to 2000 s. The sterilization process is simple and easy to operate, the method is stable, and it is ensured that the content of 5-hydroxymethylfurfural in a blood filtration replacement liquid A chamber is at a low level after sterilization; b, a chamber sterilization exposure stage: 121 DEG C is greater than 12min; the sterile standard level of the obtained glucose-containing double-chamber bag blood filtration replacement liquid reaches the standard within 18 months, the validity period reaches 18 months, and the glucose-containing double-chamber bag blood filtration replacement liquid has very good market circulation and clinical use values.

The invention discloses a three-cavity hemodiafiltration device and a hemodiafiltration method thereof, relates to the technical field of medical instruments, and aims to solve the problem that an existing double-cavity hemodiafiltration device cannot flexibly switch a replacement mode, the three-cavity hemodiafiltration device comprises a hemodiafiltration device body, the dialysis filter body comprises a first cavity, a second cavity and a third cavity which are sequentially and coaxially arranged in the blood flowing direction and communicate with one another, the interiors of the first cavity, the second cavity and the third cavity are all connected with corresponding hollow fiber membrane bundles in a sealed mode, and the two ends of the side faces of the first cavity and the third cavity are each provided with a connector. A dialysate inlet and a dialysate outlet are formed in the two ends of the side face of the second cavity respectively, so that the filter can flexibly meet the switching requirements of a front replacement mode, a rear replacement mode and a mixed replacement mode, replacement liquid is filtered again, the purity of the replacement liquid is improved, and the method further has the function of improving the dialysis effect.

The present invention pertains to an extracorporeal blood treatment device (1), preferably a hemodialysis device, hemofiltration device, or hemodiafiltration device, comprising a fluidic system (2) having a connection point (20) for adding substances, a detection arrangement (4) for detecting a flow of a substance at the connection point (20), wherein the detection arrangement is configured to generate a flow signal, when a flow of a substance is detected at the connection point (20), and a control unit (5), which is communicatively connected to the detection arrangement (4). The control unit (5) is furthermore configured to output a signal (50) in reaction to a received flow signal. The present invention furthermore pertains to a corresponding method for monitoring at least one connection point.

A parameter for controlling an inlet pump speed in a hemofiltration system is derived from fitting a line to multiple data points of pressure versus pump speed. The pressure is measured in a channel connecting an inlet pump to an outlet pump. First, the inlet pump operates and the pressure is sampled until it is stabilized, then the inlet pump speed is increased and pressure is measured to obtain a data point. Subsequently the inlet pump speed is decreased and pressure is measured to obtain another data point. A line is fit through the data points to obtain the parameter.

[Problem] To provide a hemofiltration filter that is capable of removing foreign substances such as blood clots and proteins while maintaining a sufficient blood filtration flow rate. [Solution] A mesh-type hemofiltration filter formed of resin fibers, characterized in that: the mesh number is 300 mesh or more; the aperture ratio is 30-50% inclusive; the fiber diameter of the fibers is 10-40 µm inclusive; and the weave pattern is a plain weave or a triple twill diagonal weave.

The utility model relates to a blood filtration pipeline fixing device, which belongs to the technical field of blood filtration application, and comprises a bandage, a fixing strip and a plurality of fixing blocks, the fixing blocks are fixedly arranged on the bandage, the top of each fixing block is provided with a first groove and a second groove, the first groove and the second groove are distributed in a crossed manner, the fixing blocks are provided with fixing grooves, and the fixing grooves are communicated with the first groove and the second groove. The fixing groove penetrates through the first groove, the fixing strip penetrates through the fixing groove, and one section of the fixing strip is arranged between the fixing block and the bandage. The fixing device can fix pipelines in two directions, and can adapt to pipelines of different sizes for wire arrangement.

Traditional hemofiltration devices can include a linear blood channel, a linear dialysate channel, or both. Additionally, the blood channel or dialysate channel can be modified so that one region has a recess in a channel wall and a filtration membrane can be positioned along the edge of the recess. However, due to fluid dynamics, some blood or dialysate could linger within the recess by moving slowly. Therefore, other fractions of the blood or dialysate would simply bypass the recess and filtration membrane by flowing through the center of the channel. This flow pattern would reduce filtration efficiency since some blood or dialysate remains far from the filtration membrane. However, positioning a flow diverter adjacent to the recess could force most or all of the blood or dialysate into the recess, thereby increasing filtration efficiency. In other words, the flow diverter would modify the fluid dynamics in a manner that would reduce the dead space in the blood channel or dialysate channel and increase filtration efficiency.

The invention relates to a medical device (1), preferably a dialysis apparatus for performing hemodialysis and / or hemofiltration and / or hemodiafiltration, comprising a first functional module (CPU1) and a second functional module (CPU2), wherein a chronograph (2) for counting an operating time is provided in the first functional module (CPU1) and the first functional module (CPU1) is configured to store an operating time value determined by the chronograph (2) in a first memory (M1) of the first functional module (CPU1), wherein a second memory (M2) is provided in the second functional module (CPU2), wherein the second functional module (CPU2) is configured to store the operating time value determined by the chronograph (2) of the first functional module (CPU1) in the second memory (M2).

The utility model belongs to the technical field of medical instruments, and particularly relates to a blood filtering and circulating device. According to the blood filtering and circulating device, when the switching valve enables the suction opening to be communicated with the negative pressure suction device, the negative pressure suction device works, negative pressure is generated in the thrombus filter, blood in a human body enters the thrombus filter through the thrombus suction catheter, the thrombus filter filters thrombus in the blood, after the thrombus is extracted, the negative pressure suction device stops working, and the thrombus in the human body enters the thrombus filter through the thrombus suction catheter. The switching valve enables the blood drawing port to be communicated with the blood transfusion pipeline, blood in the thrombus filter flows back to the human body through the blood transfusion pipeline, and the blood loss amount of the human body is easy to control in the operation process. Besides, the filtered blood can flow back to the human body, so that the requirement of a patient on allogenic blood transfusion is reduced, and further the infection risk and immune response related to blood transfusion are reduced; according to the blood filtering and circulating device, the mode that an injector is used for manually taking thrombus for multiple times, filtering and transfusing blood back is replaced, and the operation efficiency is improved.

1. The name of the product of this design: blood purification equipment. 2. Purpose of the product with this design: used for blood purification treatment of patients, such as hemodialysis, hemodiafiltration, hemofiltration, hemoperfusion, etc., to provide power for the extracorporeal blood circulation circuit, supply dialysate and monitor the treatment process during the treatment. 3. The design key point of this appearance design product lies in the shape. 4. The picture or photo that best illustrates the design points: Stereoscopic diagram 1. 5. The bottom surface of this design product is a part that is not easily visible or cannot be seen when in use, so the top view is omitted.

The present application relates to a kind of high-pressure discharge leak detection methods of double-chamber bag packaging system, belong to the technical field of drug detection.The method includes the following steps: preparation contains 3~10 μm pore size double-chamber positive sample and negative sample, carry out high-pressure discharge detection under (7~8) ±0.1KV output voltage, 250~300Hz frequency, respectively record minimum positive detection value M min And maximum negative detection value M max , according to formula (M min +m max ) / 2 Calculate leakage threshold (and 1.5m max ≤M min ).The present application breaks through the limitation of traditional step-by-step detection, realizes double-chamber synchronous leak detection, avoids the parameter switching and electrode error caused by chamber detection, is suitable for different pH complex preparation (such as sodium bicarbonate hemofiltration replacement fluid etc.), can detect ≥3 μm micro leakage, detection efficiency is doubled, result is accurate and reliable, and cost is significantly reduced, effectively guarantees the quality of product and clinical drug safety.

A modified hemofiltration method for clearing peripheral α-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral α-synuclein aggregates in patients with neurodegenerative diseases. Therefore, the calculation model is constructed, which provides scientific data and a new solution for clinically relieving α-synuclein-related toxicity symptoms.

The present invention relates to the technical field of blood filtration materials, and in particular to MOFs modified PBT leukocyte-removing filter material and its preparation method and application. Take aminoterephthalic acid and dissolve it in N, N-dimethylformamide, then add chitosan and ultrasonically dissolve it to obtain a mixed solution; weigh zirconium tetrachloride and dissolve it in N, N-dimethylformamide to obtain a metal salt solution, add the mixed solution to the metal salt solution and mix it evenly, after the reaction, wash, dry, and obtain UiO-66-NH2@chitosan; Take UiO-66-NH2@chitosan and add it to water to prepare a finishing liquid, take PBT non-woven fabric and immerse it in the finishing liquid, take out the PBT non-woven fabric after immersion and drying, finally wash it with deionized water, and dry it to obtain the MOFs modified leukocyte-removing PBT filter material. The filter material of the present invention has both high leukocyte filtration efficiency, red blood cell and platelet recovery rate and high efficiency antibacterial function.

Disclosed is a hemofiltration device, system and method for rapid solute removal from a patient's blood. The device, system and method employ a hemofiltration assembly for a high blood flow extracorporeal circuit, such as an ECMO circuit, configured to achieve high-efficiency, high-flux convective solute clearance, and optionally diffusive solute clearance, and include one or more hemofilters having greater filter medium surface area in a circuit having greater flow rates than previously implemented RRT modalities, and may offer rapid clearance of toxins, including those not currently dialyzable (e.g., those with high volumes of distribution).

Hemofilters for in vivo filtration of blood are disclosed. The hemofilters disclosed herein provide an optimal flow of blood through the filtration channels while maintaining a pressure gradient across the filtration channel walls to enhance filtration and minimize turbulence and stagnation of blood in the hemofilter.

The utility model discloses a blood filter blocking conversion device which comprises a pipe body and a plurality of film terminals, the upper end and the lower end of the pipe body are communicated, a puncture device is arranged on the upper portion of the pipe body, a blood return device is installed on the lower portion of the pipe body, a first connecting pipe connected with a blood filter is arranged on the side face of the pipe body, and the film terminals are connected with the first connecting pipe. The thin film terminals are installed at the pipe opening of the first connecting pipe, the thin film terminals are also installed at the upper end of the puncture device, and the blood return device is matched with the two thin film terminals; when the device is used and the blood filter needs to be replaced, only the puncture device needs to be driven to slide down, so that the puncture device is communicated with the blood return device, arterial blood does not pass through the blood filter but directly flows back through the blood return device, the blood filter can be directly replaced, and the problem of blood leakage does not need to be worried about.

1. The name of this design product: hemodialysis filter. 2. Purpose of the product of this design: Used for hemodialysis, hemofiltration, and hemodiafiltration treatment for patients with acute or chronic renal failure. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The utility model discloses an extracorporeal circulation pipeline for hemofiltration, which comprises a blood supply pipeline, an artery pot, a hemofiltration device, a vein pot with a filter screen and a blood return pipeline which are sequentially connected, a blood pump pipe is arranged on the blood supply pipeline, and a replacement liquid pipeline is further arranged on the circulation pipeline. The replacement liquid pipeline comprises a rear dilution bypass connected with the inlet end of the vein kettle and a front dilution bypass with one end connected with the rear dilution bypass and the other end connected with the inlet end of the artery kettle, and the rear dilution bypass and the front dilution bypass can be controlled through a liquid stopping clamp to input replacement liquid into the extracorporeal circulation pipeline. The pre-dilution bypass and the post-dilution bypass are simultaneously arranged on the extracorporeal circulation pipeline for hemofiltration, a pure post-dilution method can be replaced by a pure pre-dilution method, and blood clots are prevented, so that the hemofiltration time is prolonged, unplanned tube blockage is reduced, the use amount of anticoagulant is reduced, and bleeding of a patient is avoided; the treatment effect of the artificial liver is ensured.

Parallel plate devices for hemofiltration or hemodialysis are provided. A parallel plate device includes a parallel plate assembly having an aligned stack of stackable plate subunits, each stackable plate subunit having a through channel for blood, where the blood channels are opened up at opposite ends of the parallel plate assembly. The parallel plate assembly is configured to form filtrate / dialysate channels interleaved with the blood channels, adjacent channels being separated by a silicon nanoporous filtration membrane. A blood conduit adaptor is attached to the parallel plate assembly at each of the ends, and is configured to distribute blood to or collect blood from the blood channels. Also provided are systems and methods for using the parallel plate devices.

Material processing composites, devices, methods of use, and methods of manufacturing using composites having three-dimensional interpenetrating channels separated by porous walls. Such composites include composites having a first flow channel and a second flow channel defined and separated by porous (e.g., nanoporous) walls, wherein the first flow channel and the second flow channels have a three-dimensional interpenetrating structure. The first flow channel and the second flow channel may have a triply periodic minimal surface structure, such as a gyroid or Schwartz surface structure. In some embodiments, the composite is configured for use in hemofiltration, molecular filtration, gas purification, energy storage, or chemical conversion.

A system and method for preparing a cancer vaccine (and optionally purifying blood) comprises a hemofiltration system controlled by a control unit for filtering exogenous plasma to isolate tumor cells, tumor stem cells, and tumor degradation products. The hemofiltration system filter may include multiple layers with openings of different sizes to hold substances of different sizes (from among tumor cells, tumor stem cells, and tumor degradation products of different sizes). The apparatus directs electromagnetic radiation to the isolated tumor cells, tumor stem cells, and / or tumor degradation products, which can cause a coagulated outer layer by degrading the outer surface of the isolated tumor cells, isolated tumor stem cells, and / or isolated tumor degradation products (e.g., tumor proteins such as DNA and / or tumor exosomes). The electromagnetic radiation may have a UV wavelength. A conical coil improves flow uniformity. Tumor exosomes can be centrifuged.

The present invention relates to the technical field of hemodialysis, and particularly relates to a hemodiafiltration device and a leakage detection method thereof. The hemodiafiltration device includes a dialyzer, an arterial side pipeline, a venous side pipeline, an additional pipeline, and a liquid supply unit. The hemodiafiltration device can be used to implement any one of hemodialysis (HD), hemofiltration (HF), and hemodiafiltration (HDF). The leakage detection method is used to detect whether there is a leakage point in the above-mentioned hemodiafiltration device to ensure the safety of the treatment process.